## Life-Threatening Allergies, Anaphylactic Events and the **Administration of Epinephrine in School**

Massachusetts 2016-2017 School Year

## 1. Allergy Prevalance and Epinephrine Prescription Rates (Public School Students)

|  | Number of        | Percent of                       |
|--|------------------|----------------------------------|
| Type of allergy  | Students         | Enrollment                       |
| Insect sting   | 2,787            | 0.5                              |
| Food   | 38,917           | 6.6                              |
| Latex  | 1,422            | 0.2                              |
|  |                  |                                  |
| Students with epinephrine prescriptions                                  | 17,134           | 2.9                              |
|  | Number of        | 0/ (1144 11                      |
|  | Students         | % of MA public school enrollment |
| Student enrollment in districts reporting allergy and prescription data* | 587,911          | 61.6                             |
| Total MA public school enrollment  | 953,748          | 100.0                            |
| * n = 136 districts  | 300,740          | 100.0                            |
| 2. Characteristics of Individuals Who Experienced                        | l an Anaphylacti | c Event                          |
| (Public and Private Schools  |                  | 0 210/10                         |
| (i dono dia i iivato conocio   | Number of        |                                  |
| Type of person treated for anaphylaxis                                   | Individuals      | Percent of Total                 |
| Staff/Visitor  | 35               | 10.8                             |
| Student  | 289              | 89.2                             |
| TOTAL  | 324              | 100.0                            |
| Age  |                  |                                  |
| 5 or under   | 15               | 4.6                              |
| 6  | 13               | 4.0                              |
| 7  | 7                | 2.2                              |
| 8  | 13               | 4.0                              |
| 9  | 16               | 4.9                              |
| 10   | 18               | 5.6                              |
| 11   | 17               | 5.2                              |
| 12   | 33               | 10.2                             |
| 13<br>14   | 24               | 7.4<br>8.6                       |
| 15   | 28<br>36         | 11.1                             |
| 16   | 39               | 12.0                             |
| 17   | 24               | 7.4                              |
| 18 or older  | 40               | 12.3                             |
| Unknown  | 1                | 0.3                              |
| TOTAL  | 324              | 100.0                            |
| Gender   | <u> </u>         |                                  |
| Female   | 188              | 58.0                             |
| Male   | 135              | 41.7                             |
| Unknown  | 1                | 0.3                              |
| TOTAL  | 324              | 100.0                            |
| Race/Ethnicity   |                  |                                  |
| African American non-Hispanic  | 32               | 9.9                              |
| Asian non-Hispanic   | 28               | 8.6                              |
| Hispanic   | 44               | 13.6                             |
| White non-Hispanic   | 191              | 59.0                             |
| Unknown or Other   | 29               | 9.0                              |
| TOTAL  | 324              | 100.1                            |

History of life threatening allergy

| 68<br>243<br>13<br>324<br>69<br>214<br>2 | 21.0<br>75.0<br>4.0<br>100.0<br>21.3<br>66.0  |
|--|---|
| 13<br>324<br>69<br>214<br>2              | 4.0<br>100.0<br>21.3  |
| 69<br>214<br>2                           | 100.0<br>21.3   |
| 69<br>214<br>2                           | 21.3  |
| 214                                      |   |
| 214                                      |   |
| 2  | ടെ വ  |
|  |   |
|  | 0.6   |
| 39                                       | 12.0  |
| 324                                      | 100.0   |
| 100                                      | 40.7  |
| 132                                      | 40.7  |
|  | 44.8  |
|  | 14.5  |
| 324                                      | 100.0   |
| 454                                      | 47.5  |
|  | 47.5  |
|  | 35.2  |
|  | 17.3  |
| 324                                      | 100.0   |
| 70                                       | 00.7  |
|  | 22.7  |
|  | 73.3  |
|  | 4.0   |
| 322                                      | 100.0   |
|  |   |
| 160                                      | E1 0  |
|  | 51.9  |
|  | 42.6<br>5.6   |
|  | 100.0   |
| 324                                      | 100.0   |
| ctic Events                              |   |
|  |   |
|  | 64.6  |
|  | 2.2   |
|  | 2.2   |
|  | 30.9  |
| 314                                      | 100.0   |
|  |   |
|  |   |
|  | 55.2  |
|  | 2.5   |
|  | 1.9   |
|  | 3.1   |
|  | 37.3  |
| 324                                      | 100.0   |
|  |   |
| 5  | 1.6   |
| 68                                       | 21.7  |
| 144                                      | 45.9  |
| 22                                       | 7.0   |
|  |   |
| 13                                       | 4.1   |
| 13<br>62                                 | 4.1<br>19.7   |
|  |   |
|  | 145 47 324  154 114 56 324  73 236 324  73 236 13 322  168 138 18 324  203 7 7 7 97 314  179 8 6 10 121 324 |

Location where epinephrine was admininstered

| Location where epinephrine was admininstered   |                             |                                     |
|--|-----------------------------|-------------------------------------|
| Health office  | 267                         | 88.7                                |
| Other  | 34                          | 11.3                                |
| TOTAL  | 301                         | 100.0                               |
| Not reported: 23   |                             |                                     |
| Location where epinephrine was stored Health office  | 044                         | 00.0                                |
|  | 244                         | 83.0                                |
| Carried by person given epinephrine  | 48                          | 16.3                                |
| Main office or administrative office Other   | 21 37                       | 7.1<br>12.6                         |
| TOTAL  | 294                         | 12.0                                |
| Not reported: 30. *Percentages sum to more than 100% since respondents could s   |                             |                                     |
| Type of person that administered the epinephrine   | elect more than one answer. |                                     |
| Registered nurse   | 266                         | 88.4                                |
| Student  | 21                          | 7.0                                 |
| Teacher  | 8                           | 2.7                                 |
| Other  | 6                           | 2.0                                 |
| TOTAL  | 301                         | 100.0                               |
| Not reported: 23   |                             |                                     |
| Self-administration  |                             |                                     |
| Epinephrine was self-administered  | 24                          | 7.9                                 |
| Epinephrine was not self-administered  | 278                         | 92.1                                |
| TOTAL  | 302                         | 100.0                               |
| Not reported: 22   |                             |                                     |
| Time elapsed between onset of symptoms and communication symptoms  | n of                        |                                     |
| Less than or equal to 5 minutes  | 139                         | 46.3                                |
| 6 - 10 minutes   | 71                          | 23.7                                |
| 11 - 15 minutes  | 19                          | 6.3                                 |
| 16 - 30 minutes  | 22                          | 7.3                                 |
| 31 - 60 minutes  | 14                          | 4.7                                 |
| Greater than 60 minutes  | 11                          | 3.7                                 |
| Unknown  | 24                          | 8.0                                 |
| TOTAL  | 300                         | 100.0                               |
| Not reported: 24   |                             |                                     |
| Time elapsed between communication of symptoms and administr epinephrine   | ation of                    |                                     |
| Less than or equal to 5 minutes  | 126                         | 41.7                                |
| 6 - 10 minutes   | 71                          | 23.5                                |
| 11 - 15 minutes  | 31                          | 10.3                                |
| 16 - 30 minutes  | 40                          | 13.2                                |
| 31 - 60 minutes  | 30                          | 9.9                                 |
| Greater than 60 minutes  | 3                           | 1.0                                 |
| Unknown  | 1                           | 0.3                                 |
| TOTAL  | 302                         | 100.0                               |
| Not reported: 22   |                             |                                     |
| Emergency room transfer  |                             |                                     |
| L P. L. C. C. L. C. ED   |                             | 27.0                                |
| Individual was transferred to the ER   | 292                         | 97.0                                |
| Individual was not transferred to the ER   | 6                           | 2.0                                 |
| Individual was not transferred to the ER Unknown   | 6 3                         | 2.0<br>1.0                          |
| Individual was not transferred to the ER Unknown TOTAL   | 6                           | 2.0                                 |
| Individual was not transferred to the ER Unknown TOTAL Not reported: 23  | 6 3                         | 2.0<br>1.0                          |
| Individual was not transferred to the ER Unknown TOTAL Not reported: 23 Presence of a biphasic reaction  | 6<br>3<br>301               | 2.0<br>1.0<br>100.0                 |
| Individual was not transferred to the ER Unknown TOTAL Not reported: 23 Presence of a biphasic reaction A biphasic reaction occurred                               | 6<br>3<br>301<br>33         | 2.0<br>1.0<br>100.0                 |
| Individual was not transferred to the ER Unknown TOTAL Not reported: 23 Presence of a biphasic reaction A biphasic reaction occurred No biphasic reaction occurred | 3<br>301<br>33<br>151       | 2.0<br>1.0<br>100.0<br>11.2<br>51.2 |
| Individual was not transferred to the ER Unknown TOTAL Not reported: 23 Presence of a biphasic reaction A biphasic reaction occurred                               | 6<br>3<br>301<br>33         | 2.0<br>1.0<br>100.0                 |

Second dose of epinephrine

| A second epinephrine dose was required     | 37  | 12.5  |
|--|-----|-------|
| A second epinephrine dose was not required | 184 | 62.2  |
| Unknown                                    | 75  | 25.3  |
| TOTAL                                      | 296 | 100.0 |
| Not reported: 28                           |     |       |

Notes for Section 1: 1) While the epinephrine administration data in sections 2 and 3 are the main focus of this report, allergy prevalence and epinephrine prescription data are included here to put those administrations in context. Note that the allergy and prescription data are only available for public school districts affiliated with the Essential School Health Services program, and while these data include more than 60% of the state's public school population, they may not be representative of the entire state. 2) Charter schools and collaboratives are counted as districts for purposes of this report. 3) For consistency, the allergy prevalence and epinephrine prescription rates that are shown in the table only include districts that reported data in both categories. 4) For calculating allergy prevalence, a student may be counted as having an allergy even if that student has never experienced an anaphylactic reaction.

Notes for Sections 2 and 3: 1) These data show the number of epinephrine administrations due to suspected anaphylactic events. 2) These data are compiled from reports of epinephrine administration submitted by public and private schools throughout Massachusetts, and are not limited to schools participating in the Essential School Health Services program. 3) An online data collection tool is used to faciliate the collection of epinephrine administration data. 4) "Other" race/ethnicity includes American Indian/Alaskan Native and Native Hawaiian/Other Pacific Islander. 5) "Not reported" indicates that the respondent skipped the question or failed to complete the questionnaire, and as a result, nothing can be inferred from the answer. "Unknown" is a response option, however, and indicates that the respondent answered the question by selecting "unknown." If a response was "not reported" it is also "unknown," but not all "unknown" answers are "not reported."

Note for Sections 1, 2, and 3: Percentages may not sum to 100% due to rounding.